Related Experiment Video

Updated: Feb 25, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.5K

MicroRNA Dysregulation in Alzheimer's Disease

Manish Putteeraj1, Yahaya Mohamad Fairuz2, Seong Lin Teoh2

  • 1School of Health Sciences, University Technology of Mauritius, Pointe aux Sables, Mauritius.

CNS & Neurological Disorders Drug Targets
|August 8, 2017
PubMed
Abstract

Insights

MicroRNAs (miRNAs) are implicated in Alzheimer's disease (AD) pathophysiology. Identifying dysregulated miRNA patterns offers potential for novel AD diagnostic biomarkers and therapeutic targets.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alzheimer's disease (AD) is a major global health challenge.
  • AD pathogenesis involves interactions between beta-amyloid peptide, Tau protein, and genetic/environmental factors.
  • MicroRNAs (miRNAs) are emerging as key regulators in neurodegenerative diseases, including AD.

Purpose of the Study:

  • To review recent studies on dysregulated miRNAs in Alzheimer's disease.
  • To explore the role of miRNAs in AD pathophysiology, specifically in beta-amyloid and Tau toxicity.

Main Methods:

  • Literature review of studies identifying dysregulated miRNAs in AD.
  • Analysis of miRNA involvement in beta-amyloid and Tau pathways.

Main Results:

  • Numerous miRNAs have been identified as dysregulated in Alzheimer's disease.
  • These miRNAs are potentially significant contributors to beta-amyloid and Tau toxicity.

Conclusions:

  • Dysregulated miRNA patterns can serve as specific biomarkers for AD diagnosis.
  • miRNAs represent promising targets for the development of new AD therapeutics.
Keywords:
Alzheimer diseaseTauopathybiomarkermicroRNAtreatmentβ-amyloid

More Related Videos

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice09:13

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice

Published on: July 11, 2025

31.1K
Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections07:55

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Published on: November 8, 2024

924

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K